On July 27, 2021 Avecho Biotechnology Limited (ASX:AVE) reported its Quarterly Activities Report and 4C for the quarter ended 30 June 2021 (Press release, Phosphagenics, JUL 27, 2021, View Source [SID1234585208]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The continued development of our soft-gel CBD product has been the main focus for the Company during this period, resulting in the achievement of a number of key milestones:

CBD soft-gel capsule design finalised by Catalent Pharma Solutions
TGA meeting activities planned to gain feedback on CBD program
Recruitment on the CACOS observational clinical trial continued – 130 patients were enrolled in the trial by the end of June.
Independent of our CBD program, Avecho also made progress in the animal health space, with our potential partner AB Vista looking at opportunities to take our TPM technology to the animal feed market.

Our cash balance at the close of the quarter was $4.8m.

Avecho remains committed to its R&D programs, while continuing to demonstrate prudent cash management and adapt its operational policies and procedures in line with COVID-19 mitigation measures.